Review

Therapeutics candidates and repurposing strategies to target parkinson’s disease pathology: current evidence and future directions

Yarava Dhanush N. Nizamuddin S. Neelima S. Kalpana Kalyan Kumar Arla V. Ganesh P. Sree Chennuru Rohitha

Sep 2026 · Metabolic brain disease · Vol 41 · 0 citations · 73 references

Medicine

TL;DR

This review aimed to comprehensively examine the current evidence for repurposed drugs, clinically investigated therapeutic candidates, and repositioning strategies targeting the principal pathological hallmarks of Parkinson’s disease, and propose mechanistic frameworks for rational combination therapy, and outline future directions for trial design and biomarker integration.

DOI PubMed Semantic Scholar

View source

Similar papers

Review Sep 2026

Analysis of multidimensional molecular mechanisms in Parkinson's disease and precise therapeutic strategies.

Current mechanistic insights inspire targeted therapeutic strategies comprising α-synuclein inhibitors, mitochondrial protectants, anti-inflammatory agents, and novel cell death pathway blockers, alongside gut-brain axis interventions for PD, but these approaches face substantial challenges.

Xin Chen, Zi-Hao Zhao, Yun-Tian Shen et al. · Experimental Neurology · 0 citations

Review Open access Aug 2026

Neuroprotective Potential of Semaglutide in Parkinson’s Disease: Mechanisms, Preclinical Evidence, and Clinical Perspectives

A narrative review evaluates the therapeutic potential of semaglutide in PD, focusing on its molecular mechanisms and preclinical and emerging clinical evidence, and suggests that semaglutide crosses the blood-brain barrier and activates GLP-1 receptors in neuronal and glial cells, reducing microglial activation, neuro...

Dipesh Kumar, Renuka Sahu, Naveen Kumar et al. · International Journal of Sci... · 0 citations

Review Aug 2026

Multitargeted drug strategies for Alzheimer’s and Parkinson’s diseases

Recent advances in multitarget drug development for AD and PD targeting compounds targeting Aβ, BACE1, MAO-B, cholinesterases, metal-ion dyshomeostasis, oxidative stress, and inflammatory pathways are reviewed.

Azmatullah Khan, Abdullah Abdullah, Syeda Farwa Naqvi et al. · Zeitschrift für Naturforschu... · 0 citations

Review

Advances in Modern Biomedicine

The urgent need for reliable biomarkers, early diagnosis, and multidisciplinary disease-modifying strategies for future therapeutic interventions is highlighted, with particular emphasis on challenges associated with bench-to-bedside translation.

Jeewanjot Singh, Subhi Sharma, Prabhjot Singh et al. · 0 citations

Review Aug 2026

Nanotechnology-enabled delivery of bioactive compounds for neuroprotection in Parkinson's disease: mechanisms and future directions.

This approach aims not only to control symptoms but also to potentially control neurodegeneration in PD, and the major challenges include large-scale production, long-term safety assessment, regulatory challenges, and site-specific delivery.

P. Gaur, Prachee Raje Bisht, Sonia Lal Gupta · Journal of Biomaterials Scie... · 0 citations

Review Open access Sep 2026

Neuroinflammation and metabolic reprogramming in Parkinson’s disease

An integrative model in which neuroinflammation and metabolic dysfunction function not merely in parallel, but as mutually reinforcing components of a self-amplifying pathological circuit is proposed, while acknowledging that this model remains to be fully validated and that alternative causal architectures are possibl...

Yi-Xin Fu, Jiang-Hao Yu, Lu Xu et al. · Frontiers in Immunology · 0 citations